Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Hemophilia C

  • Author: Paula H B Bolton-Maggs, DM, FRCPath, FRCP; Chief Editor: Robert J Arceci, MD, PhD  more...
 
Updated: Oct 13, 2015
 

Background

Hemophilia C (deficiency of factor XI) was described first in 2 sisters and a maternal uncle of an American Jewish family. All 3 bled after dental extractions, and the sisters also bled after tonsillectomy. (See Etiology and Epidemiology.)

Even in severe deficiency of factor XI, the bleeding tendency is mild. Unlike the bleeding tendency in hemophilia A or hemophilia B, which is clearly related to the factor level, the bleeding risk in hemophilia C is not always influenced by the severity of the deficiency, especially in individuals with partial deficiency. Indeed, some patients with severe deficiency do not have a bleeding tendency, whereas some patients with mild deficiency bleed excessively.

This unpredictability, which is not fully understood, makes hemophilia C more difficult to manage than hemophilia A or B.[1]

Severe deficiency is defined as factor XIc activity of 15-20 U/dL or lower. However, this is no longer suitable terminology since the bleeding disorder is not clinically severe, even at very low levels of factor XI. Spontaneous bleeding rarely occurs, but bleeding may occur after surgery, more commonly in those with the lowest levels. The levels in this range, less than about 15 U/dL, generally identify individuals who have 2 FXI gene mutations. Patients with partial deficiency, generally heterozygous with a single FXI gene mutation, have levels of about 20-60 U/dL (ie, the lower limit of the normal range). About 30-50% of individuals with partial deficiency may have excessive bleeding; however, identifying these persons in advance is difficult. Furthermore, normal infants without hemophilia C are likely to have low factor XIc levels until they are older than 6 months. (See Etiology and History andPhysicalExamination.)

Brenner et al used a logistic regression model to analyze parameters influencing bleeding tendency in subjects with factor XI deficiency from 45 families.[2] Odds ratios for bleeding were 13 in homozygotes or double heterozygotes and 2.6 in heterozygotes. Bleeding was negatively correlated with the level of factor XI, and severe factor XI deficiency was a strong predictor of bleeding. Minor factor XI deficiency and blood group O contributed minimally to bleeding. levels of factor VIII and von Willebrand factor were not predictors of bleeding. Bleeding was most common after surgical procedures involving mucosal membranes.

Other possible explanations for variations in patient bleeding tendencies include the following:

  • Additional clotting factor disorders, especially von Willebrand disease, or a more subtle change in hemostatic balance
  • Variant factor XI molecules (ie, those with a discrepancy between factor XI clotting activity compared with antigen): These variants are rare, and no correlation between mutation type and bleeding tendency has been identified.
  • Increased fibrinolysis at certain surgical sites

With regard to the last item, factor XI deficiency has been associated with bleeding problems after surgery or trauma to areas of the body in which the fibrinolytic activity is particularly high (eg, urogenital tract, oral cavity after dental extraction or tonsillectomy). Hence, women can present with menorrhagia or with bleeding related to childbirth or gynecologic surgery. (See History and Physical Examination and Treatment.)

Go to Acquired Hemophilia, Hemophilia A, and Hemophilia B for complete information on these topics.

Complications

Complications of factor XI deficiency commonly involve the unpredictable nature of bleeding.

Patients who receive plasma products may be at risk for contracting unknown, virally transmissible infections.

Patients with absent factor XI may also develop inhibitors to factor XI.

In addition, some patients (with preexisting risk factors) who receive factor XI concentrates may be at risk for thrombotic events.

Prognosis

The prognosis is excellent in patients with partial factor XI deficiency without bleeding manifestations.

Next

Etiology

The severity of the deficiency is based on plasma factor XIC (clotting) activity. Severe factor XI deficiency is present when the activity of factor XI in plasma is less than 1-15 IU/dL.

Factor XI is a dimeric serine protease, which is composed of chains that each weigh 80,000 Da. Factor XIIa activates factor XI and factor IX in the original intrinsic pathway of blood coagulation. Also, thrombin directly activates factor XI, and this direct activation may be more important than the activation due to factor XII. Recently, it has been shown that thrombin activation of factor XI is triggered by polyphosphate release from activated platelets. These molecules provide a template for assembly of factor XI and factor IX. Patients with factor XII deficiency, even severe deficiency, do not necessarily have a tendency to bleed. Hence, the absence of factor XII appears to be irrelevant to factor XI.

Factor XI is a zymogen that, on activation, undergoes conversion to a serine protease that leads to activation of factor IX, followed by thrombin generation. The sustained generation of thrombin also leads to the activation of thrombin-activatable fibrinolysis inhibitor (TAFI), which impairs the conversion of plasminogen to plasmin. Thus, factor XI serves as a procoagulant and an antifibrinolytic agent, and the lack of factor XI in plasma results in a tendency to bleed. People with severe factor XI deficiency have a lower incidence of ischemic stroke.[3]

Factor XI has no role in the complement or kinin pathways but has been shown to activate fibrinolysis. Alpha-1 antitrypsin is the main inhibitor of factor XIa and is responsible for two thirds of its inhibition. C1 esterase inhibitor, antithrombin III, and alpha-2 antiplasmin cause the remaining inhibition.

In severe deficiency factor XI, bleeding is related to injury, especially when trauma involves tissues rich in fibrinolytic activators, such as the oral mucosa, the nose, and the urinary tract. Unlike patients with severe hemophilia A or B, patients with severe factor XI deficiency do not spontaneously bleed.

Gene mutations

Mutations in the factor XI gene cause the congenital deficiency of factor XI clotting activity.[4] The inheritance pattern of factor XI is autosomal but not completely recessive, because heterozygotes may have bleeding.[5]

The gene for factor XI is near the gene for prekallikrein on the distal arm of chromosome 4 (4q35). It is 23 kb, with 15 exons and 14 introns. Factor XI is synthesized in the liver and circulates in the plasma as a complex with high-molecular-weight kininogen. Factor XI has a half-life of about 52 hours.

The first 3 mutations in the factor XI gene were described in 6 persons of Ashkenazi Jewish descent who were severely affected.

More than 200 other mutations that cause factor XI deficiency have been described and are listed in online databases.

Databases include Mutations of Patients with Factor XI Deficiency, which is maintained by the University of North Carolina School of Medicine, and www.factorxi.org, an interactive database maintained by University College London. The published mutations include missense mutations, nonsense mutations, deletions and/or insertions, and splice-site mutations. Those described so far are associated mainly with failed or reduced production of the active protein, and only a few are related to the production of a dysfunctional molecule.

Four mutations (types I-IV) have been identified in people of Ashkenazi Jewish descent. Two of these mutations occur with increased frequency in this population. Type II, which is a nonsense mutation (Glu117stop) is prevalent in Ashkenazi and Iraqi Jews. Type III, a missense mutation (Phe283Leu), is present only in Ashkenazi Jews. Homozygotes for type II or type III mutations have a factor XI activity of 1 and 10 U/dL, respectively, whereas compound heterozygotes for type II or type III have factor XI activity of 3-5 U/dL.

Various mutations have been identified in persons who are not Jewish. Two ancestral mutations are described: a mutation with a Cys38Arg substitution in exon 3 (observed in the French Basque Country) and the mutation C128X in exon 5 (occurring in England).[5] Both mutations result in a factor XI level of less than 1 U/dL in affected homozygotes.

People with mutations leading to absent protein (eg, Glu117Stop, C128X) are at risk of development of inhibitors (antibodies) to factor XI; this should be considered when selecting treatment for these patients.

Acquired factor XI deficiency occurs in patients who develop inhibitors to this protein, as is sometimes observed in patients with systemic lupus erythematosus or other immunologic diseases.

Factor XI deficiency is a common finding in patients with Noonan syndrome, which is characterized by congenital cardiac abnormalities, short stature, and mental retardation.

Previous
Next

Epidemiology

Hemophilia C (severe form) occurs with an estimated prevalence of 1 case per 100,000 population in the United States, a rate that makes hemophilia A 10 times more common than hemophilia C.

Internationally, deficiency of factor XI is reported in most racial groups, with the highest frequency in persons of Ashkenazi or Iraqi Jewish descent[6, 7] ; in Israel, the estimated rate for heterozygosity is 8%. In the United Kingdom national database, 1696 patients (many of whom were non-Jewish) with factor XI deficiency were registered in a population of about 60 million (data for 2006), but most of these have partial deficiency[8] ; factor XI deficiency is more common than factor IX deficiency (hemophilia B). In the French Basque country (home to the most ancient ethnic group of Western Europe, the Basques), 39 patients were identified among the general population of 290,000.[9]

Hemophilia C equally affects males and females.

People of any age group can be affected. Note that normal infants younger than age 6 months have low levels of factor XI because of the time required for factor XI to reach normal levels observed in adults. After this is reached, factor XI levels do not change with age.

Previous
Next

Patient Education

Patients must be counseled about the unpredictable nature of their bleeding tendency, and they should be informed of the preparations needed before elective surgery.

The usual precautions regarding physical activity for individuals with a bleeding disorder apply to patients with factor XI deficiency who have a bleeding tendency. Patients should be encouraged to wear seat belts, to use protective gear (eg, bike helmets), and to avoid contact sports.

Patients should be advised to keep up to date with their vaccinations, especially hepatitis A virus and hepatitis B virus vaccinations.

Stress the importance of annual visits to hemophilia treatment centers.

Patients should receive genetic counseling with regard to their marriage partners and the potential risks to their offspring.

For patient education information, see Hemophilia.

Previous
 
 
Contributor Information and Disclosures
Author

Paula H B Bolton-Maggs, DM, FRCPath, FRCP Consultant Hematologist, Medical Director, Serious Hazards of Transfusion, Haemovigilance Scheme for the UK

Paula H B Bolton-Maggs, DM, FRCPath, FRCP is a member of the following medical societies: American Society of Hematology, International Society on Thrombosis and Haemostasis

Disclosure: Received honoraria from BPL for speaking and teaching.

Coauthor(s)

Prasad Mathew, MBBS, DCH, FAAP Professor of Pediatrics, Division of Hematology/Oncology, University of New Mexico School of Medicine

Prasad Mathew, MBBS, DCH, FAAP is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society of Hematology, American Society of Pediatric Hematology/Oncology, International Society on Thrombosis and Haemostasis, American Society of Clinical Oncology, National Hemophilia Foundation, Hemophilia and Thrombosis Research Society, International Society of Paediatric Oncology, World Federation of Hemophilia

Disclosure: Received salary from Bayer HC for payment for services rendered.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Gary D Crouch, MD Associate Professor, Program Director of Pediatric Hematology-Oncology Fellowship, Department of Pediatrics, Uniformed Services University of the Health Sciences

Gary D Crouch, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Hematology

Disclosure: Nothing to disclose.

Chief Editor

Robert J Arceci, MD, PhD Director, Children’s Center for Cancer and Blood Disorders, Department of Hematology/Oncology, Co-Director of the Ron Matricaria Institute of Molecular Medicine, Phoenix Children’s Hospital; Editor-in-Chief, Pediatric Blood and Cancer; Professor, Department of Child Health, University of Arizona College of Medicine

Robert J Arceci, MD, PhD is a member of the following medical societies: American Association for the Advancement of Science, American Association for Cancer Research, American Pediatric Society, American Society of Hematology, American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

References
  1. Zucker M, Seligsohn U, Salomon O, Wolberg AS. Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency. J Thromb Haemost. 2014 Jul. 12 (7):1121-30. [Medline].

  2. Brenner B, Laor A, Lupo H, Zivelin A, Lanir N, Seligsohn U. Bleeding predictors in factor-XI-deficient patients. Blood Coagul Fibrinolysis. 1997 Nov. 8(8):511-5. [Medline].

  3. Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood. 2008 Apr 15. 111(8):4113-7. [Medline].

  4. Guella I, Solda G, Spena S, et al. Molecular characterization of two novel mutations causing factor XI deficiency: A splicing defect and a missense mutation responsible for a CRM+ defect. Thromb Haemost. 2008 Mar. 99(3):523-30. [Medline].

  5. Bolton-Maggs PH, Patterson DA, Wensley RT, Tuddenham EG. Definition of the bleeding tendency in factor XI-deficient kindreds--a clinical and laboratory study. Thromb Haemost. 1995 Feb. 73(2):194-202. [Medline].

  6. Asakai R, Chung DW, Ratnoff OD, Davie EW. Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations. Proc Natl Acad Sci U S A. 1989 Oct. 86(20):7667-71. [Medline]. [Full Text].

  7. Gomez K, Bolton-Maggs P. Factor XI deficiency. Haemophilia. 2008 Nov. 14(6):1183-9. [Medline].

  8. Bolton-Maggs PH, Peretz H, Butler R, et al. A common ancestral mutation (C128X) occurring in 11 non-Jewish families from the UK with factor XI deficiency. J Thromb Haemost. 2004 Jun. 2(6):918-24. [Medline].

  9. Bauduer F, Dupreuilh F, Ducout L, Marti B. Factor XI deficiency in the French Basque Country. Haemophilia. 1999 May. 5(3):187-90. [Medline].

  10. Peyvandi F, Di Michele D, Bolton-Maggs PH, Lee CA, Tripodi A, Srivastava A. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost. 2012 Sep. 10(9):1938-43. [Medline].

  11. Batty P, Honke A, Bowles L, et al. Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centres. Haemophilia. 2015 Jul. 21 (4):490-5. [Medline].

  12. Bauduer F, de Raucourt E, Boyer-Neumann C, et al. Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study. Haemophilia. 2015 Jul. 21 (4):481-9. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.